Pro Share Advisors LLC Avadel Pharmaceuticals PLC Transaction History

Pro Share Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$7.34 - $11.18 $91,581 - $139,492	-12,477 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$6.49 - $9.91 $12,869 - $19,651	1,983 Added 18.9%	12,477 $122,000
Q2 2021 Aug 13, 2021	BUY	$6.73 - $9.05 $70,624 - $94,970	10,494 New	10,494 $71,000
Q4 2018 Feb 14, 2019	SELL	$1.74 - $4.66 $29,731 - $79,625	-17,087 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$4.08 - $7.14 $1,974 - $3,455	-484 Reduced 2.75%	17,087 $75,000
Q2 2018 Aug 13, 2018	SELL	$5.89 - $7.78 $8,728 - $11,529	-1,482 Reduced 7.78%	17,571 $108,000
Q1 2018 May 14, 2018	SELL	$6.76 - $11.7 $20,854 - $36,094	-3,085 Reduced 13.94%	19,053 $139,000
Q4 2017 Feb 14, 2018	SELL	$8.03 - $11.25 $5,564 - $7,796	-693 Reduced 3.04%	22,138 $182,000
Q3 2017 Nov 13, 2017	BUY	$8.35 - $10.5 $17,351 - $21,819	2,078 Added 10.01%	22,831 $240,000
Q2 2017 Aug 11, 2017	BUY	N/A	20,753	20,753 $229,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.